# Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

> **NCT02483208** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 18 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** BAY81-8973
- **DRUG:** Advate

## Key facts

- **NCT ID:** NCT02483208
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2015-07
- **Final completion:** 2015-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483208, "Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02483208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*